PRMT5 Carboxamide Inhibitors for MTAP-Deleted Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRMT5 inhibitors are unable to selectively target cancer cells with MTAP deletion, leading to potential systemic liabilities and hematologic toxicity, as they either compete with SAM or lack cooperation with MTA, necessitating the development of potent and selective MTA-cooperative PRMT5 inhibitors.
Innovation Solution
Development of 5-amino-1H-pyrrolo[3,2-b]pyridine-2-carboxamide derivatives that act as PRMT5 inhibitors, selectively targeting cancer cells with MTAP deletion by forming a tertiary complex with MTA, thereby inhibiting PRMT5 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PRMT5 inhibitors are used to inhibit PRMT5 activity, then PRMT5 inhibition is achieved, but selective targeting of cancer cells with MTAP deletion is not achieved, leading to systemic toxicity and hematologic toxicity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (amino group at position 5, carboxamide at position 2, heteroaryl substituents) that enable selective binding to the MTA-PRMT5 complex only in cancer cells with MTAP deletion. This localized molecular design ensures the drug acts selectively on the target population of cancer cells while sparing normal cells, thereby resolving the contradiction between achieving PRMT5 inhibition and avoiding systemic toxicity.
Solution Approach 2:
The patent utilizes MTA (methylthioadenosine) as an intermediary that accumulates specifically in cancer cells with MTAP deletion. The inhibitors are designed to cooperate with MTA by binding to the MTA-PRMT5 complex, forming a stable ternary complex. This intermediary mechanism allows selective targeting: normal cells without MTA accumulation cannot form the ternary complex, thus avoiding toxicity, while cancer cells with high MTA levels undergo potent PRMT5 inhibition.
2Reliability
If PRMT5 inhibitors are designed to compete with SAM, then PRMT5 inhibition is achieved, but selectivity for MTAP-deleted cancer cells is lost
Solution Approach 1:
The patent segments the inhibition mechanism into two distinct binding events: first, MTA binds to the SAM pocket of PRMT5, and second, the inhibitor binds to the MTA-PRMT5 complex. This segmentation allows the inhibitor to exploit the pre-formed MTA-PRMT5 complex for selective binding, rather than competing directly with SAM. The segmented mechanism enables both effective PRMT5 inhibition and selectivity for MTAP-deleted cancer cells where MTA accumulates.
Solution Approach 2:
The patent applies preliminary action by requiring MTA to bind to PRMT5 first, forming the MTA-PRMT5 complex before the inhibitor can bind. This preliminary binding event creates a unique molecular target that only exists in cancer cells with MTAP deletion. The inhibitor is designed to recognize and bind to this pre-formed complex, ensuring selectivity while maintaining inhibition efficacy.
3Reliability
If non-MTA cooperative PRMT5 inhibitors are used, then PRMT5 inhibition is achieved, but cooperation with MTA for selective targeting is not achieved
Solution Approach 1:
The patent merges two inhibition mechanisms into a single cooperative system: MTA binding to PRMT5 and inhibitor binding to the MTA-PRMT5 complex. This merging creates a ternary complex that combines the selective targeting capability of MTA (which accumulates only in MTAP-deleted cancer cells) with the potent inhibition capability of the inhibitor. The combined mechanism achieves both selective targeting and effective PRMT5 inhibition, avoiding the toxicity associated with non-selective inhibitors.
Data Source
AI summary
This disclosure provides compounds containing 5-AMINO-1H-PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE derivatives as MTA-cooperative inhibitors of PRMT5, the use thereof for selectively inhibiting the activity of PRMT5 in cooperative with MTA in tumors bearing MTAPDEL mutation, and pharmaceutical compositions comprising the compounds as treatment of various diseases including cancer.